Optogenetic and chemogenetic regulation of uterine vascular function

子宫血管功能的光遗传学和化学遗传学调控

• 批准号: 10785667
• 负责人: Ramon Lorca
• 金额: $ 42.9万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-19 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10785667
• 关键词: Acceleration; Acute; Address; Adverse effects; Affect; Agonist; Altitude; Animal Genetics; Animal Model; Animals; Area; Arteries; Blood Vessels; Blood flow; Bluetooth; Cardiovascular Diseases; Cardiovascular system; Cell membrane; Cervical; Child; Chronic Disease; Contralateral; Development; Drug Design; Elderly; Endothelial Cells; Endothelium; Exposure to; Fetal Growth; Fetal Growth Retardation; Fetal Reduction; Fetus; Fiber; Foundations; G alpha q Protein; G-Protein-Coupled Receptors; Genetic; Genetic Models; Genotype; Goals; Growth; Halorhodopsins; Human; Hypertension; Hypoxia; Impairment; Implant; Invaded; Knowledge; Life; Light; Longevity; Measures; Microfluidics; Molecular; Morphology; Mothers; Mus; Muscarinic Acetylcholine Receptor; Muscarinic M3 Receptor; Neonatal Mortality; Nitric Oxide; Opsin; Optics; Pericytes; Physiological; Placenta; Population; Positioning Attribute; Predisposition; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnant Uterus; Proliferating; Pump; Regulation; Relaxation; Reproducibility; Reproductive Health; Risk; Signaling Protein; Smooth Muscle; Smooth Muscle Myocytes; Stress; Techniques; Testing; Therapeutic; Time; Uterus; Vagus nerve structure; Vasodilation; Wild Type Mouse; cardiovascular disorder risk; design; experimental study; fetal; fetal blood; flexibility; genetic technology; genetically modified cells; healthy pregnancy; implantation; improved; in vivo; infant morbidity/mortality; innovation; internal control; microbial; mouse model; neonatal death; novel; novel therapeutics; optogenetics; perinatal period; pharmacologic; pregnant; prevent; receptor; skull implant; stillbirth; subcutaneous; therapeutically effective; therapy development; tool; trophoblast; vascular bed

PROJECT SUMMARY Fetal growth restriction (FGR) increases the risk of stillbirth and neonatal death. The adverse effects of being born FGR extend well beyond the perinatal period, increasing the risk of cardiovascular disease, among others, in later life. Impaired vascular adaptation to pregnancy is a predominant contributor to FGR. Hypoxic conditions also alter uteroplacental vascular function, reducing fetal growth, similarly to FGR. To understand the mechanisms by which an increase in uterine artery (UtA) blood flow can prevent hypoxia-dependent impaired uterine vasculature and reduced fetal growth, we propose using optogenetics and chemogenetics technology for manipulating uterine blood flow in live animals. Optogenetics is an innovative technique in which genetically modified cells express light-activated microbial opsins (e.g., halorhodopsin [NpHR]), which can then be selectively stimulated by light in vivo. Chemogenetics utilizes modified receptors such as the muscarinic M3 receptor (hM3Dq), which can be selectively activated by specific agonists (e.g., deschloroclozapine [DCZ]). Our goal is to develop novel and reliable murine models to prevent FGR via endothelium or smooth muscle-specific mechanisms in the UtA. To address this goal, we propose to conduct two scientific aims. In Aim 1, in mice expressing NpHR in the smooth muscle, we will address the capacity for light stimulation to vasodilate the UtA in vivo, increasing UtA blood flow and preventing FGR. Aim 2 will determine the effect of endothelium-dependent UtA vasodilation via expression of hM3Dq and its selective activation by DCZ locally applied through a microfluidic channel. Current murine models for increasing UtA blood flow in vivo require pharmacological activations that are non-tissue specific, and the timing of the activation cannot be controlled. Our optogenetic and chemogenetic models will provide better control of the degree of blood flow manipulation, enhanced reproducibility among experiments, improved selectivity of the stimulation, and the opportunity to test the timing of stimulation. This project will be the first to apply optogenetics and chemogenetics to the vasodilation of UtA in vivo. Importantly, our proposal can provide the foundation for applying optogenetics and chemogenetics to the study of other vascular beds in vivo.

项目概要 胎儿生长受限（FGR）会增加死产和新生儿死亡的风险。存在的不利影响 出生的 FGR 远远超出围产期，增加了心血管疾病等疾病的风险， 在以后的生活中。血管对妊娠的适应受损是 FGR 的主要原因。缺氧条件 与 FGR 类似，也会改变子宫胎盘血管功能，减少胎儿生长。要了解 增加子宫动脉（UtA）血流量可预防缺氧依赖性受损的机制 子宫脉管系统和胎儿生长减少，我们建议使用光遗传学和化学遗传学技术 操纵活体动物的子宫血流。光遗传学是一种创新技术，其中基因 修饰后的细胞表达光激活的微生物视蛋白（例如盐视紫红质 [NpHR]），然后可以将其 在体内受光选择性刺激。化学遗传学利用修饰受体，例如毒蕈碱 M3 受体 (hM3Dq)，可以被特定激动剂（例如去氯氯氮平 [DCZ]）选择性激活。我们的 目标是开发新颖且可靠的小鼠模型，通过内皮或平滑肌特异性来预防 FGR UtA 中的机制。为了实现这一目标，我们建议实现两个科学目标。在目标 1 中，在小鼠中 在平滑肌中表达 NpHR，我们将解决光刺激使 UtA 血管舒张的能力 在体内，增加 UtA 血流量并预防 FGR。目标 2 将确定内皮依赖性的效果 UtA 血管舒张通过 hM3Dq 的表达及其通过 DCZ 局部应用的选择性激活来实现。 微流体通道。目前增加体内 UtA 血流量的小鼠模型需要药理学 非组织特异性的激活，并且激活的时间无法控制。我们的光遗传学 化学遗传学模型将更好地控制血流操纵程度，增强 实验之间的可重复性、改进的刺激选择性以及测试时机的机会 的刺激。该项目将是第一个将光遗传学和化学遗传学应用于 UtA 血管舒张的项目 体内。重要的是，我们的建议可以为应用光遗传学和化学遗传学提供基础 体内其他血管床的研究。